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Efficacy and Safety of Alirocumab Versus Ezetimibe
Over 2 Years (from ODYSSEY COMBO II)
Mahfouz El Shahawy, MDa,*, Christopher P. Cannon, MDb, Dirk J. Blom, MMed, PhDc,
James M. McKenney, PharmDd, Bertrand Cariou, MD, PhDe, Guillaume Lecorps, MScf,
Robert Pordy, MDg, Umesh Chaudhari, MDh, and Helen M. Colhoun, MDi
The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to
substantially reduce low-density lipoprotein cholesterol (LDL-C). Demonstrating whether
efficacy and safety are maintained over a long duration of exposure is vital for clinical
decision-making. The COMBO II trial compared the efficacy and safety of alirocumab
versus ezetimibe over 2 years. A prespecified first analysis was reported at 52 weeks. Here
we report the final end-of-study data (on-treatment) and evaluate post hoc the safety
profile with longer versus shorter duration of alirocumab exposure. Patients (n = 720) on
maximally tolerated statin dose were treated with alirocumab (75/150 mg every 2 weeks)
or ezetimibe (10 mg/day). Overall mean adherence for both treatment groups during the
first and second year was >97%. At 2 years, LDL-C was reduced by 49% (alirocumab)
versus 17% (ezetimibe; p <0.0001), and LDL-C <70 mg/dl was achieved by 73% of alirocumab-
treated versus 40% of ezetimibe-treated patients. Overall safety was similar in both
treatment groups at 2 years and during the first versus the second year. Local injection-
site reactions were reported by 2.5% (alirocumab) versus 0.8% (ezetimibe) during the
first year, and 0.2% versus 0.5% during the second year, indicating early occurrence
during prolonged alirocumab exposure. Two consecutive calculated LDL-C values <25 mg/
dl were observed in 28% of alirocumab-treated patients (vs 0.4% with ezetimibe). Persistent
anti-drug antibody responses were observed in 1.3% (6 of 454) of alirocumab-treated
versus 0.4% (1 of 231) of ezetimibe-treated patients. Neutralizing antibodies (that inhibit
binding in vitro) were observed in 1.5% (7 of 454) of alirocumab-treated patients (0 with
ezetimibe), mostly at isolated time points. Alirocumab sustained substantial LDL-C reduc-
tions and was well tolerated up to 2 years in the COMBO II trial. © 2017 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2017;■■:■■–■■)
Alirocumab, a proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitor, reduces low-density lipoprotein cho-
lesterol (LDL-C) levels by up to 61% in addition to
statins ± lipid-lowering therapies.1–3 The ODYSSEY Phase 3
COMBO II (NCT01644188) trial evaluated the efficacy and
safety of alirocumab versus ezetimibe in reducing LDL-C in
patients at high risk of cardiovascular (CV) events on maxi-
mally tolerated statin dose (MTD, defined in the supplement)
who were not at pre-specified LDL-C target levels.4,5 At 24
weeks, alirocumab reduced LDL-C by 51% (vs 21% with
ezetimibe), corresponding to achieved LDL-C levels of
52 mg/dl and 83 mg/dl, respectively.4 An important consid-
eration is whether the number and nature of adverse events
(AEs) change following long-term alirocumab exposure,
considering the recent data on the variability in efficacy and
AEs related to immunogenicity seen on treatment with
bococizumab, another PCSK9 antibody.6,7 Here we report the
final end-of-study efficacy and safety data from the COMBO
II trial to evaluate whether the effect of alirocumab versus
ezetimibe is sustained for up to 2 years. We also compared
post hoc the treatment adherence, safety, and the incidence
of AEs in the first year versus the second year of the study.
Methods
Detailed methods and patient disposition have been re-
ported previously (Figure 1).4,5 Briefly, the multinational,
multicenter, double-blind, active controlled, parallel-group
study included patients with hypercholesterolemia and es-
tablished coronary heart disease (CHD; defined in the
Supplement) or CHD risk equivalents (ischemic stroke, pe-
ripheral artery disease, moderate chronic kidney disease, or
diabetes mellitus plus ≥2 additional risk factors) not at Na-
tional Cholesterol Education Program, Adult Treatment Panel
III goal despite stable MTD for ≥4 weeks before the screen-
ing visit. The goal for patients with documented CV disease
was LDL-C <70 mg/dl, or <100 mg/dl for patients without
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a documented history of CV disease but at high CV risk. CV
disease was defined as CHD, ischemic stroke, or peripheral
artery disease.
Patients (n = 720) were randomized 2:1 to receive double-
blind treatment for 2 years with either subcutaneous alirocumab
75 mg (in 1-ml volume) every 2 weeks (Q2W) (plus oral
placebo for ezetimibe daily) or 10 mg oral ezetimibe daily
(plus placebo subcutaneous Q2W for alirocumab) and con-
tinued to receive their background statin therapy. At week 12,
the alirocumab dose was automatically increased to 150 mg
Q2W (1-ml volume) if the week 8 LDL-C value was
≥70 mg/dl, while maintaining subject and investigator blind-
ing. There was an 8-week posttreatment observation period
following the 2-year (104-week) double-blind period. The pro-
tocol was approved by the institutional review boards of
participating centers. All participants gave written informed
consent. Race was self-reported in this study.
The primary end point was percentage change in calcu-
lated LDL-C from baseline to week 24, using all LDL-C values
regardless of adherence to treatment (intent-to-treat [ITT] ap-
proach) and has been published previously.4 Here, we report
percentage change in calculated LDL-C from baseline up to
2 years by on-treatment analysis. For the on-treatment analy-
sis, changes in lipoprotein values during the efficacy treatment
period were assessed using the modified ITT population,
defined as all randomized patients who received at least 1 dose
or part of a dose of the double-blind study treatment and had
an evaluable primary efficacy end point during the treat-
ment period (defined as the period ending at last injection date
+ 21 days or last capsule administration date + 3 days, which-
ever comes first). The primary efficacy end point was evaluated
when both baseline and at least 1 calculated LDL-C value
on-treatment (during the efficacy period and within 1 of the
analysis windows up to 2 years) were both available. Per-
centage changes in apolipoprotein (Apo) B, high-density
lipoprotein cholesterol (HDL-C), lipoprotein(a) (Lp[a]), non–
HDL-C, triglycerides, and Apo A1 from baseline to 2 years
are also reported (on-treatment analysis).
The overall treatment adherence for injections was defined
during the treatment period for each patient as follows: 100
− (percentage of days with below-planned dosing + percent-
age of days with above-planned dosing). Overall treatment
adherence rates were analyzed in the first (weeks 0 to 52) and
second (weeks 52 to 104) years of treatment (further details
in the Supplement). Safety was assessed by analyzing AE
reports and laboratory analyses from the time of signed in-
formed consent until the end of the study. AEs were defined
as treatment-emergent if they developed, worsened, or became
serious during the period between first and last dose of study
treatment (planned at week 102) plus 10 weeks (further details
in the Supplement).
In addition to overall AE rates up to the end of the study,
we also compared (post hoc) the rates of AEs in the first year
(weeks 0 to 56) versus the second year (weeks 56 to 112) of
the study. If a patient had an event once during weeks 0 to
56 and once during weeks 56 to 112, the 2 events were ana-
lyzed separately in the respective time period in which they
occurred. Although the last treatment dose was at week 102,
Figure 1. Consolidated Standards of Reporting Trials flow diagram. Patient disposition of the study population. AE = adverse event; ITT = intent to treat;
mITT = modified intent to treat; Q2W = every 2 weeks.
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residual effect of alirocumab is expected until 10 weeks after
the last injection. The AE follow-up period is 8 weeks fol-
lowing the end-of-treatment visit at week 104; hence, the
overall study period was up to 112 weeks. A comparison
between weeks 0 to 56 and weeks 56 to 112 was used to allow
for equal periods of treatment duration.
The presence of anti-drug antibodies (ADAs) was evalu-
ated at weeks 0, 12, 24, 52, and 104 using a validated, titer-
based immunoassay (sensitivity ~5 ng/ml; Regeneron
Pharmaceuticals, Inc., Tarrytown, NY; assay details in the
Supplement and as reported previously8). A persistent ADA
response was defined as 2 consecutive positive postbaseline
responses separated by a minimum of 12 weeks. Samples posi-
tive for ADAs were further examined for neutralizing
antibodies (NAbs), which are ADAs that inhibit the binding
of alirocumab to PCSK9 in vitro (assay details in the Supple-
ment and previously reported8).
All statistical analyses were performed by Sanofi at the
direction of the independent investigators, who had access
to any relevant data analysis on request in this study. Statis-
tical analyses have been described previously.4,5 A mixed-
effect model with repeated measures was used to compare
changes in LDL-C and other lipoproteins assumed to be nor-
mally distributed between alirocumab and ezetimibe patient
groups over 2 years. Lipoproteins assumed to be non-
normally distributed (i.e., triglycerides and Lp[a]) were
analyzed using multiple imputation to handle missing data
followed by robust regression model.
Results
Demographic characteristics, disease characteristics, and
lipid parameters at baseline were generally similar in the
alirocumab group compared with the ezetimibe group, and
have been reported previously.4 Mean (standard deviation [SD])
age at screening was 62 (9.3) years, 74% were male, and 85%
were white. Mean (SD) baseline LDL-C levels were 109 (37)
and 105 (34) mg/dl in the alirocumab (n = 479) and ezetimibe
(n = 241) groups, respectively (Table S1 in the Supplement).
Atherosclerotic cardiovascular disease (ASCVD), which
included CHD, ischemic stroke, and peripheral arterial disease,
was documented in 95% of patients. Of the total popula-
tion, 81% had hypertension and 31% had investigator-
reported type 2 diabetes mellitus (defined by medical history,
Table S1 in the Supplement).
Exposure to investigational medical product injections with
≥102 weeks’ duration was observed in 79% (378 of 479) and
78% (187 of 241) of alirocumab- and ezetimibe-treated pa-
tients, respectively. Exposure to investigational medical product
capsules with ≥102 weeks’ duration was observed in 81% (381
of 472) and 79% (187 of 237) of alirocumab- and ezetimibe-
treated patients, respectively.
The overall mean (SD) treatment adherence over 2 years
was high in both groups: 98% (5.1) for the alirocumab-
treated and 98% (3.5) for the ezetimibe-treated group. The
majority of patients in the alirocumab (98%) and ezetimibe
(99%) groups had at least 80% adherence for injections (i.e.,
patients received ≥80% of their injections on schedule). Simi-
larly, 96% of alirocumab-treated and 98% of ezetimibe-
treated patients had at least 80% adherence for capsules. There
was no difference in treatment adherence between the first
year and the second year of treatment. The overall mean (SD)
treatment adherence for both treatment groups during the first
and second year of treatment was >97%. The percentage of
patients with ≥80% adherence for injections was 99% for both
the alirocumab and the ezetimibe groups during the first year
and 99% and 98%, respectively, during the second year. Simi-
larly, the percentage of alirocumab-treated patients with ≥80%
adherence for capsules was 97% (vs 99% ezetimibe-treated)
during the first year and 97% (vs 98% ezetimibe-treated)
during the second year.
In the on-treatment analysis, LDL-C was reduced from
baseline to week 24 by 52% with alirocumab versus 22% with
ezetimibe (least squares [LS] mean difference of −31%, 95%
confidence interval [CI] −35 to −26; p <0.0001; Figure 2).
A sustained effect of alirocumab was observed on calcu-
lated LDL-C over 2 years with reductions of 49% versus 17%
with ezetimibe at 2 years (LS mean difference of −32%, 95%
CI −38 to −26; p <0.0001; Figure 1, Table S2 in the Supple-
ment). Alirocumab treatment for 2 years resulted in mean
(standard error) calculated LDL-C values of 54 (1.8) mg/dl
versus 87 (2.6) mg/dl on ezetimibe treatment (p <0.0001).
LDL-C <70 mg/dl was achieved by 73% of alirocumab-
treated versus 40% of ezetimibe-treated patients at 2 years.
Significant (p <0.0001) reductions from baseline up to 2
years were observed in Lp(a), Apo B, and non–HDL-C levels,
whereas HDL-C levels significantly (p <0.0001) increased with
alirocumab versus ezetimibe treatment (LS mean difference
of +7.4% for percent change from baseline at 2 years,
Figures 2). Triglycerides were reduced from baseline to 2 years
by 8.2% in the alirocumab group and by 11.4% in the
ezetimibe group, but the difference between treatment arms
was not statistically significant (Figure 2).
Over the course of the whole study period, AEs were re-
ported by 391 (82%) alirocumab-treated versus 198 (82%)
ezetimibe-treated patients, and serious AEs were reported by
124 (26%) versus 60 (25%) patients, respectively. AEs leading
to death occurred in 6 (1.3%) alirocumab-treated versus 6
(2.5%) ezetimibe-treated patients, and AEs leading to dis-
continuation of study treatment occurred in 44 (9.2%) versus
19 (7.9%) patients, respectively (Table 1).
In AEs of interest, higher rates were observed with
alirocumab versus ezetimibe for injection-site reactions and
allergic reactions (Table 1). Cataract conditions were ob-
served in 10 (2.1%) alirocumab-treated and 6 (2.5%)
ezetimibe-treated patients. Single elevations of alanine and
aspartate aminotransferase were observed at higher frequen-
cies with alirocumab versus ezetimibe, whereas creatinine
kinase levels were comparable between the 2 groups (Table 1).
A comparison of AE rates between the first year and the
second year of the study period identified local injection-site re-
actions in 12 (2.5%) alirocumab-treated versus 2 (0.8%)
ezetimibe-treated patients during the first year, compared with
1 (0.2%) alirocumab-treated versus 1 (0.5%) ezetimibe-treated
patient during the second year (Table 2). Of the 12 injection-
site reactions reported by alirocumab-treated patients during the
first year, 11 (92%) were of mild intensity (vs 2 [100%] in the
ezetimibe group) and 1 (8.3%) was of moderate intensity
(Table S3 in the Supplement). During the second year, the single
(100%) injection-site reaction reported in the alirocumab group
was of mild intensity (vs 1 [100%] of severe intensity in the
ezetimibe group, Table S3 in the Supplement).
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Over the complete 2 years of follow-up, there was no mean-
ingful difference between treatment groups over the study
period for ophthalmological events, neurological or
neurocognitive disorders, hepatic disorders, or AEs related
to diabetes or diabetic complications (Table 1, Table S4 in
the Supplement). Overall rates of specific AEs were similar
in the alirocumab and ezetimibe groups for the first and the
second year (Table 2). In other AEs of interest, rates were
similar in the first and the second year of the study (Table 2).
At least 2 consecutive LDL-C values <25 mg/dl were ob-
served in 128 (28%) patients in the alirocumab group
(including 45 [9.8%] patients with 2 consecutive LDL-C values
<15 mg/dl), of whom 91 (71%) reported at least 1 AE after
the first LDL-C <25 mg/dl value (Table 3). The median time
to the first calculated LDL-C value <25 mg/dl and <15 mg/
dl was 12 and 16 weeks, respectively. Most patients were on
75 mg Q2W alirocumab at the time of the first LDL-C value
<25 mg/dl (90%) and <15 mg/dl (88%). Of the 351
alirocumab-treated patients with LDL-C ≥25 mg/dl, 288 (82%)
reported any AE (Table 3). The AE profile in patients with
2 consecutive LDL-C values <25 mg/dl was not notably dif-
ferent from the overall population or from patients with LDL-
C ≥ 25 mg/dl, and no safety concerns were reported (Table 3).
There were no injection-site reactions reported in these pa-
tients: 2 (1.6%) patients with 2 consecutive values of LDL-C
<25 mg/dl versus 7 (2.0%) patients with LDL-C ≥25 mg/dl
who reported cataracts. One ezetimibe-treated patient had 2
consecutive LDL-C <25 mg/dl values (time to the first value
Figure 2. On-treatment analysis of (A) mean change in calculated LDL-C, and mean percent change from baseline in (B) Lp(a), (C) Apo B, (D) non–HDL-
C, (E) HDL-C, and (F) triglycerides over 2 years. *p <0.0001 vs ezetimibe. Changes in lipoproteins versus study time points on treatment with alirocumab
and ezetimibe. Values above and below the data points indicate the percentage reduction from baseline, with percentage differences indicated by the values
next to the arrows. Apo = apolipoprotein; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a);
LS = least squares; SE = standard error.
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of LDL-C < 25 mg/dl was 52 weeks); this patient did not report
any AEs.
Persistent ADA responses were observed in 1.3% (6 of 454)
of patients administered alirocumab versus 0.4% (1 of 231)
of patients administered ezetimibe, with median time of onset
being 12 and 52 weeks, respectively (Table S5). The first ADA
response was observed in the first year (weeks 0 to 56) of
treatment for all patients. ADA responses observed exhib-
ited low titers, resolved over time, and had no clinical impact
on either pharmacokinetics or safety of alirocumab. At least
1 NAb response was observed in 1.5% (7 of 454) of
alirocumab-treated patients (mostly at single, isolated time
points); no NAb responses were observed in ezetimibe-
treated patients (Table S5). NAbs detected by immunoassays
were transient and at isolated time points.
Discussion
These data indicate that the efficacy and safety of
alirocumab are maintained through 2 years in high-risk pa-
tients when administered in addition to MTD at 75 mg Q2W,
with potential increase to 150 mg Q2W based on individual
LDL-C responses at week 8.
Overall treatment adherence was high in both treatment
groups and did not vary between the first and the second year
of the treatment period. In the on-treatment analysis,
alirocumab resulted in sustained LDL-C reductions and goal
achievement compared with ezetimibe, demonstrating supe-
riority of treatment in patients at high CV risk not at LDL-C
treatment goal. The slight decrease observed in efficacy at 2
years compared with efficacy at 24 weeks in the alirocumab-
treated group was also observed in the ezetimibe-treated group.
The changes in atherogenic lipid levels observed in this
study are consistent with those in the overall ODYSSEY trials.9
Each LDL particle contains a molecule of Apo B. Uptake of
LDL-C and other Apo B-containing lipids occurs via the LDL
receptor. PCSK9 promotes degradation of the LDL recep-
tor, hence alirocumab-mediated inhibition of PCSK9 increases
LDL receptor availability resulting in reduced levels of
not only LDL-C but also Apo B.10 Non–HDL-C (total
Table 1
Frequency of adverse events from baseline to end of study (safety population)
Variable Alirocumab (n = 479) Ezetimibe (n = 241)
Any AE 391 (81.6%) 198 (82.2%)
Treatment–emergent SAE 124 (25.9%) 60 (24.9%)
AE leading to death 6 (1.3%) 6 (2.5%)
AE leading to permanent treatment discontinuation 44 (9.2%) 19 (7.9%)
AEs of special interest*
Local injection-site reactions 13 (2.7%) 3 (1.2%)
General allergic reactions 38 (7.9%) 17 (7.1%)
Hemolytic anemia 0 0
Neurological events 19 (4.0%) 11 (4.6%)
Neurocognitive disorders 6 (1.3%) 5 (2.1%)
Ophthalmological events 9 (1.9%) 4 (1.7%)
Hepatic disorders 19 (4.0%) 11 (4.6%)
AEs related to diabetes mellitus or diabetic complications 35 (7.3%) 19 (7.9%)
Patients with diabetes at baseline n = 148 n = 77
Any AE 17 (11.5%) 10 (13.0%)
Patients without diabetes at baseline n = 331 n = 164
Any AE 18 (5.4%) 9 (5.5%)
MACE† 23 (4.8%) 8 (3.3%)
CHD death 4 (0.8%) 2 (0.8%)
Non-fatal MI 16 (3.3%) 5 (2.1%)
Ischemic stroke 2 (0.4%) 1 (0.4%)
Unstable angina requiring hospitalization 1 (0.2%) 1 (0.4%)
Ischemia driven coronary revascularization procedure‡ 21 (4.4%) 7 (2.9%)
Laboratory parameters§
Alanine aminotransferase >3 x ULN 10/470 (2.1%) 2/240 (0.8%)
Aspartate aminotransferase >3 x ULN 11/470 (2.3%) 1/240 (0.4%)
Creatine kinase >3 x ULN 17/467 (3.6%) 8/236 (3.4%)
n (%) = number and percentage of patients with at least 1 AE.
* Certain AEs were grouped as AEs of special interest (prespecified in the ODYSSEY phase 3 study protocols), based on identified, potential, and theo-
retical risks for the new drug class collected during the clinical trial program. AEs related to diabetes mellitus or diabetic complications are regardless of
baseline status. Based on standard or custom Medical Dictionary of Regulatory Activities queries.
† Number and percentage of patients with at least 1 MACE (coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring
hospitalization).
‡ Ischemia-driven coronary revascularization procedure related to coronary artery bypass grafting and percutaneous coronary intervention if the reason for
procedure is new episode of ischemia occurring after randomization.
§ The denominator for each parameter within a treatment group is the number of patients who had that parameter assessed after baseline (not missing)
during the AE period.
AE = adverse event; CHD = coronary heart disease; MACE = major adverse cardiac event; MI = myocardial infarction; SAE = serious adverse event; ULN = upper
limit of normal.
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cholesterol minus HDL-C) is largely composed of LDL-C,
and hence is also reduced with alirocumab. Studies also in-
dicate that the increase in LDL receptors observed with
alirocumab treatment may increase catabolism of Lp(a).11,12
However, as statins reduce LDL-C but have little effect on
Lp(a), other evidence suggests that Lp(a) reductions from
PCSK9 inhibition may also be mediated by pathways not in-
volving the LDL receptor.13,14 An increase in HDL-C observed
with alirocumab may be attributed to decreased LDL avail-
able to interact with cholesterol.15,16
Overall AEs at 2 years were mostly comparable between
the 2 treatment groups, except for injection-site reactions and
allergic reactions. Glycemic control over 2 years of treat-
ment in all individuals with and without diabetes from
COMBO II has been analyzed in a separate study.17 Median
fasting glucose and glycated hemoglobin values up to 2 years
in those with and without diabetes were comparable between
treatment groups.17 The slightly increased rate of injection-
site reactions in alirocumab-treated patients was seen only
in the first year of the study, indicating that these reactions
occur early during exposure. The decreased rate of injection-
site reactions in the second compared with the first year was
unlikely to be due to treatment discontinuation. The AE rates
seen in patients with 2 consecutive calculated LDL-C values
of <25 mg/dl were similar to the overall alirocumab-treated
population.
Administration of alirocumab 75 mg Q2W or 75 mg in-
creased to 150 mg Q2W as an add-on therapy over 2 years
Table 2
Frequency of adverse events in patients who received alirocumab versus ezetimibe reported at first (weeks 0 to 56) and second year (weeks 56 to 112)
Variable Alirocumab Ezetimibe
Weeks 0–56
(n = 479)
Weeks 56–112
(n = 411)
Weeks 0–56
(n = 241)
Weeks 56–112
(n = 209)
Any AE 343 (71.6%) 249 (60.6%) 166 (68.9%) 129 (61.7%)
Treatment–emergent SAE 87 (18.2%) 55 (13.4%) 40 (16.6%) 30 (14.4%)
AE leading to death 2 (0.4%) 4 (1.0%) 6 (2.5%) 2 (1.0%)
AE leading to permanent treatment discontinuation 39 (8.1%) 5 (1.2%) 15 (6.2%) 5 (2.4%)
AEs occurring in ≥5% of patients in any of the groups
Infections and infestations 128 (26.7%) 75 (18.2%) 61 (25.3%) 67 (32.1%)
Upper respiratory tract infection 31 (6.5%) 14 (3.4%) 13 (5.4%) 6 (2.9%)
Musculoskeletal and connective tissue disorders 93 (19.4%) 64 (15.6%) 41 (17.0%) 25 (12.0%)
Myalgia 21 (4.4%) 6 (1.5%) 13 (5.4%) 0
Nervous system disorders 78 (16.3%) 39 (9.5%) 38 (15.8%) 24 (11.5%)
Dizziness 21 (4.4%) 9 (2.2%) 13 (5.4%) 6 (2.9%)
Gastrointestinal disorders 76 (15.9%) 37 (9.0%) 30 (12.4%) 31 (14.8%)
Injury, poisoning, and procedural complications 58 (12.1%) 46 (11.2%) 34 (14.1%) 20 (9.6%)
Accidental overdose 29 (6.1%) 22 (5.4%) 17 (7.1%) 5 (2.4%)
Cardiac disorders 58 (12.1%) 26 (6.3%) 28 (11.6%) 21 (10.0%)
General disorders and administration site conditions 56 (11.7%) 24 (5.8%) 25 (10.4%) 13 (6.2%)
Respiratory, thoracic, and mediastinal disorders 43 (9.0%) 20 (4.9%) 21 (8.7%) 16 (7.7%)
Investigations 38 (7.9%) 20 (4.9%) 23 (9.5%) 7 (3.3%)
Skin and subcutaneous tissue disorders 34 (7.1%) 19 (4.6%) 15 (6.2%) 4 (1.9%)
Vascular disorders 34 (7.1%) 27 (6.6%) 21 (8.7%) 14 (6.7%)
Metabolism and nutrition disorders 32 (6.7%) 19 (4.6%) 18 (7.5%) 10 (4.8%)
Psychiatric disorders 21 (4.4%) 9 (2.2%) 12 (5.0%) 4 (1.9%)
Eye disorders 21 (4.4%) 10 (2.4%) 6 (2.5%) 11 (5.3%)
Renal and urinary disorders 20 (4.2%) 17 (4.1%) 12 (5.0%) 8 (3.8%)
AEs of special interest*
General allergic reaction 29 (6.1%) 13 (3.2%) 12 (5.0%) 5 (2.4%)
AEs related to diabetes mellitus or diabetic complications† 24 (5.0%) 13 (3.2%) 10 (4.1%) 9 (4.3%)
Neurological 13 (2.7%) 7 (1.7%) 6 (2.5%) 5 (2.4%)
Local injection-site reactions 12 (2.5%) 1 (0.2%) 2 (0.8%) 1 (0.5%)
Hepatic disorders 11 (2.3%) 9 (2.2%) 7 (2.9%) 6 (2.9%)
Ophthalmological 7 (1.5%) 2 (0.5%) 1 (0.4%) 3 (1.4%)
Neurocognitive disorder 3 (0.6%) 4 (1.0%) 4 (1.7%) 1 (0.5%)
Weeks 56 to 112 included double-blind treatment up to week 104 plus an 8-week follow-up. To have equal time periods for comparison, AEs were ana-
lyzed for weeks 0 to 56 and weeks 56 to 112. If a patient had an event once in weeks 0 to 56 and once in weeks 56 to 112, the 2 events were recorded
separately in the respective time period they occurred.
* Certain AEs were grouped as AEs of special interest (prespecified in the phase 3 study protocols), based on identified, potential, and theoretical risks for
the new drug class collected during the clinical trial program. These included local injection-site reactions, general allergic events, neurological events, hepatic
disorders, and ophthalmological events. Other predefined categories, including AEs related to neurocognitive disorders and diabetes mellitus, were analyzed
in the same way as the other AEs of interest, but not specifically defined as AEs of special interest in the protocols. AEs related to diabetes mellitus or dia-
betic complications are regardless of baseline status. Based on standard or custom Medical Dictionary of Regulatory Activities queries.
† AEs related to diabetes mellitus or diabetic complications are regardless of baseline status.
AE = adverse event; SAE = serious adverse event.
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was associated with low levels of immunogenicity. NAb re-
sponses identified by immunoassays were transient and
observed in 7 alirocumab-treated patients. These responses
do not necessarily impact clinical efficacy; however, a robust
analysis of the efficacy of alirocumab by ADA status in this
study was not possible because of the low patient numbers.
In a pooled analysis of 10 ODYSSEY Phase 3 trials with 4747
patients, including the COMBO II study, ADA and NAb re-
sponses occurred at a low rate and were transient, occurring
at single time points.8 In the overall ODYSSEY program, mean
reductions in LDL-C were maintained over time in patients
with persistent and NAb responses.8 Overall, the results of
the post hoc safety analysis up to 2 years reported here are
comparable with those reported previously up to 1.5 years
(78 weeks) in the ODYSSEY LONG TERM study.1 The
similar safety profile of alirocumab- and ezetimibe-treated pa-
tients in the later time period of the study should be interpreted
cautiously, as patients with AEs reported in the first year may
have discontinued treatment. This study was not powered for
analysis of CV events. Pooled post hoc analysis from the
ODYSSEY program indicated a 24% risk reduction in major
adverse CV events per 39 mg/dl lower LDL-C level (hazard
ratio 0.79, 95% CI 0.63 to 0.91).18 In this study, LDL-C was
reduced by 53 mg/dl with alirocumab at 2 years. Recent clini-
cal outcomes results with other PCSK9 inhibitors have yielded
promising results.6,19 The ongoing ODYSSEY OUTCOMES
study has randomized approximately 18,000 patients to
alirocumab or placebo to evaluate the effect of treatment on
major adverse CV events.20 These end-of-study data from
COMBO II provide important information for clinicians and
patients on the efficacy and safety of alirocumab co-
administered with MTD.
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